CLINICAL_TRIALS
trial_result
· 2012-01-10
Clinical Trial Update: Atopic Dermatitis Biomarker Identification Trial in Omalizumab Usage [Phase 2]
Summary
A Phase 2 biomarker identification trial evaluating omalizumab in Atopic Dermatitis has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Technical University of Munich | Conditions: Atopic Dermatitis, Atopic Eczema | Phase 2 | Status: COMPLETED